Judith Mensah Panford, MD
Hospitalist · Wilmington, DENPI 1629607593
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 26 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 10 manufacturers, the largest accounting for just 20.0% — the pattern of someone who eats at a lot of different presentations.
Across 26 payments — averaging $17.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$94
- Novo Nordisk$69
- Exact Sciences$60
- Lilly USA, LLC$54
- Johnson & Johnson$52
- Otsuka America Pharmaceutical, Inc.$47
- plus $91 from 4 others
What the payments were for
- Food & beverage$467100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 5 | $94 |
| Novo Nordisk | 4 | $69 |
| Exact Sciences | 3 | $60 |
| Lilly USA, LLC | 3 | $54 |
| Johnson & Johnson | 3 | $52 |
| Otsuka America Pharmaceutical, Inc. | 3 | $47 |
| GSK | 2 | $32 |
| Seqirus USA Inc | 1 | $26 |
| Astellas Pharma US Inc | 1 | $21 |
| Pfizer | 1 | $13 |
How this compares
$467 in reported general payments places this provider in the 85th percentile of 43 hospitalist providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 38 | $377 |
| Rosuvastatin Calcium | 30 | $283 |
| Gabapentin | 13 | $241 |
| Levothyroxine Sodium | 14 | $230 |
| Amlodipine Besylate | 32 | $229 |
| Metoprolol Tartrate | 18 | $210 |
| Trazodone Hcl | 16 | $161 |
| Losartan Potassium | 12 | $131 |
| Lisinopril | 14 | $130 |
| Fluticasone Propionate | 12 | $119 |
| Furosemide | 17 | $68 |
| Sumatriptan Succinate | 12 | $32 |
| Hydrochlorothiazide | 11 | $15 |
Paid to pharmacies, not to this prescriber.
Other hospitalist in Wilmington
- Ricki CarrollWilmington$29K
- Kimberly McMahonWilmington$748
- Ekta AgarwalWilmington$114
- David RappaportWilmington$23
- Amanda WalkerWilmington$21
- David WestWilmington$15
- Maria PetriniWilmington$14
- Ryan HoltonWilmington$0
- Zoya IqbaluddinWilmington$0
- Alfred QuezadaNewark$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.